Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Jump to content

Editing Dolutegravir/rilpivirine

You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to a username, among other benefits.
Content that violates any copyrights will be deleted. Encyclopedic content must be verifiable through citations to reliable sources.
Latest revision Your text
Line 25: Line 25:
| DailyMedID = Juluca
| DailyMedID = Juluca
| pregnancy_AU = B1
| pregnancy_AU = B1
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Dolutegravir / rilpivirine (Juluca) Use During Pregnancy | website=Drugs.com | date=7 January 2020 | url=https://www.drugs.com/pregnancy/dolutegravir-rilpivirine.html | access-date=25 March 2020 | archive-date=25 March 2020 | archive-url=https://web.archive.org/web/20200325190543/https://www.drugs.com/pregnancy/dolutegravir-rilpivirine.html | url-status=live }}</ref><ref name="Juluca AU PI" />
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Dolutegravir / rilpivirine (Juluca) Use During Pregnancy | website=Drugs.com | date=7 January 2020 | url=https://www.drugs.com/pregnancy/dolutegravir-rilpivirine.html | access-date=25 March 2020}}</ref><ref name="Juluca AU PI" />
| pregnancy_category=
| pregnancy_category=
| routes_of_administration = [[Oral administration|By mouth]]
| routes_of_administration = [[Oral administration|By mouth]]
Line 34: Line 34:
<!-- Legal status -->
<!-- Legal status -->
| legal_AU = S4
| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Juluca | website=NPS MedicineWise | date=15 July 2021 | url=https://www.nps.org.au/medicine-finder/juluca#full-pi | access-date=13 February 2022 | archive-date=14 February 2022 | archive-url=https://web.archive.org/web/20220214020912/https://www.nps.org.au/medicine-finder/juluca#full-pi | url-status=live }}</ref><ref name="Juluca AU PI">{{cite web | url=http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1 | title=TGA eBS - Product and Consumer Medicine Information Licence | access-date=14 February 2022 | archive-date=14 February 2022 | archive-url=https://web.archive.org/web/20220214015418/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1 | url-status=live }}</ref>
| legal_AU_comment = <ref>{{cite web | title=Juluca | website=NPS MedicineWise | date=15 July 2021 | url=https://www.nps.org.au/medicine-finder/juluca#full-pi | access-date=13 February 2022}}</ref><ref name="Juluca AU PI">{{cite web | url=http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1 | title=TGA eBS - Product and Consumer Medicine Information Licence }}</ref>
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{cite web | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00438 | title=Regulatory Decision Summary for Juluca | website=Drug and Health Product Register | date=23 October 2014 | access-date=7 June 2022 | archive-date=7 June 2022 | archive-url=https://web.archive.org/web/20220607071913/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00438 | url-status=live }}</ref><ref>{{cite web | title=Drug and medical device highlights 2018: Helping you maintain and improve your health | website=[[Health Canada]] | date=14 October 2020 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html | access-date=17 April 2024 | archive-date=17 April 2024 | archive-url=https://web.archive.org/web/20240417063539/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html | url-status=live }}</ref>
| legal_CA_comment = <ref>{{cite web | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00438 | title=Regulatory Decision Summary for Juluca | website=Drug and Health Product Register | date=23 October 2014 }}</ref><ref>{{cite web | title=Drug and medical device highlights 2018: Helping you maintain and improve your health | website=[[Health Canada]] | date=14 October 2020 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2018.html | access-date=17 April 2024}}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment =
| legal_DE_comment =
Line 44: Line 44:
| legal_NZ_comment =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK = POM
| legal_UK_comment = <ref>{{cite web | title=Juluca 50 mg/25 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=25 February 2020 | url=https://www.medicines.org.uk/emc/product/9246/smpc | access-date=25 March 2020 | archive-date=25 March 2020 | archive-url=https://web.archive.org/web/20200325190542/https://www.medicines.org.uk/emc/product/9246/smpc | url-status=live }}</ref>
| legal_UK_comment = <ref>{{cite web | title=Juluca 50 mg/25 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=25 February 2020 | url=https://www.medicines.org.uk/emc/product/9246/smpc | access-date=25 March 2020}}</ref>
| legal_US = Rx-only
| legal_US = Rx-only
| legal_US_comment = <ref name="Juluca FDA label" />
| legal_US_comment = <ref name="Juluca FDA label" />
Line 73: Line 73:
The most common adverse reactions (of all severity grades) are [[diarrhea]] and headache.<ref name="Juluca FDA label" />
The most common adverse reactions (of all severity grades) are [[diarrhea]] and headache.<ref name="Juluca FDA label" />


Dolutegravir/rilpivirine was approved for use in the United States in November 2017,<ref name="Juluca FDA label">{{cite web | title=Juluca- dolutegravir sodium and rilpivirine hydrochloride tablet, film coated | website=DailyMed | date=24 October 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=806653d1-bf35-4924-b999-ad5d21821cc1 | access-date=25 March 2020 | archive-date=12 June 2020 | archive-url=https://web.archive.org/web/20200612235833/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=806653d1-bf35-4924-b999-ad5d21821cc1 | url-status=live }}</ref><ref>{{cite web | title=Drug Approval Package: Juluca (dolutegravir and rilpivirine) | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 June 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210192Orig1s000TOC.cfm | access-date=25 March 2020 | archive-date=25 March 2020 | archive-url=https://web.archive.org/web/20200325190543/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210192Orig1s000TOC.cfm | url-status=live }}</ref><ref>{{cite web | title=Juluca: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210192 | access-date=25 March 2020 | archive-date=15 August 2020 | archive-url=https://web.archive.org/web/20200815020710/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210192 | url-status=live }}</ref> and for use in the European Union in May 2018.<ref name="Juluca EPAR">{{cite web | title=Juluca EPAR | website=[[European Medicines Agency]] (EMA) | date=11 February 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/juluca | access-date=25 March 2020 | archive-date=25 March 2020 | archive-url=https://web.archive.org/web/20200325190542/https://www.ema.europa.eu/en/medicines/human/EPAR/juluca | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>
Dolutegravir/rilpivirine was approved for use in the United States in November 2017,<ref name="Juluca FDA label">{{cite web | title=Juluca- dolutegravir sodium and rilpivirine hydrochloride tablet, film coated | website=DailyMed | date=24 October 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=806653d1-bf35-4924-b999-ad5d21821cc1 | access-date=25 March 2020}}</ref><ref>{{cite web | title=Drug Approval Package: Juluca (dolutegravir and rilpivirine) | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 June 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210192Orig1s000TOC.cfm | access-date=25 March 2020}}</ref><ref>{{cite web | title=Juluca: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210192 | access-date=25 March 2020}}</ref> and for use in the European Union in May 2018.<ref name="Juluca EPAR">{{cite web | title=Juluca EPAR | website=[[European Medicines Agency]] (EMA) | date=11 February 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/juluca | access-date=25 March 2020}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>
__TOC__
__TOC__


By publishing changes, you agree to the Terms of Use, and you irrevocably agree to release your contribution under the CC BY-SA 4.0 License and the GFDL. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel Editing help (opens in new window)

Copy and paste: – — ° ′ ″ ≈ ≠ ≤ ≥ ± − × ÷ ← → · §   Cite your sources: <ref></ref>


{{}}   {{{}}}   |   []   [[]]   [[Category:]]   #REDIRECT [[]]   &nbsp;   <s></s>   <sup></sup>   <sub></sub>   <code></code>   <pre></pre>   <blockquote></blockquote>   <ref></ref> <ref name="" />   {{Reflist}}   <references />   <includeonly></includeonly>   <noinclude></noinclude>   {{DEFAULTSORT:}}   <nowiki></nowiki>   <!-- -->   <span class="plainlinks"></span>


Symbols: ~ | ¡ ¿ † ‡ ↔ ↑ ↓ • ¶   # ∞   ‹› «»   ¤ ₳ ฿ ₵ ¢ ₡ ₢ $ ₫ ₯ € ₠ ₣ ƒ ₴ ₭ ₤ ℳ ₥ ₦ № ₧ ₰ £ ៛ ₨ ₪ ৳ ₮ ₩ ¥   ♠ ♣ ♥ ♦   𝄫 ♭ ♮ ♯ 𝄪   © ® ™
Latin: A a Á á À à  â Ä ä Ǎ ǎ Ă ă Ā ā à ã Å å Ą ą Æ æ Ǣ ǣ   B b   C c Ć ć Ċ ċ Ĉ ĉ Č č Ç ç   D d Ď ď Đ đ Ḍ ḍ Ð ð   E e É é È è Ė ė Ê ê Ë ë Ě ě Ĕ ĕ Ē ē Ẽ ẽ Ę ę Ẹ ẹ Ɛ ɛ Ǝ ǝ Ə ə   F f   G g Ġ ġ Ĝ ĝ Ğ ğ Ģ ģ   H h Ĥ ĥ Ħ ħ Ḥ ḥ   I i İ ı Í í Ì ì Î î Ï ï Ǐ ǐ Ĭ ĭ Ī ī Ĩ ĩ Į į Ị ị   J j Ĵ ĵ   K k Ķ ķ   L l Ĺ ĺ Ŀ ŀ Ľ ľ Ļ ļ Ł ł Ḷ ḷ Ḹ ḹ   M m Ṃ ṃ   N n Ń ń Ň ň Ñ ñ Ņ ņ Ṇ ṇ Ŋ ŋ   O o Ó ó Ò ò Ô ô Ö ö Ǒ ǒ Ŏ ŏ Ō ō Õ õ Ǫ ǫ Ọ ọ Ő ő Ø ø Œ œ   Ɔ ɔ   P p   Q q   R r Ŕ ŕ Ř ř Ŗ ŗ Ṛ ṛ Ṝ ṝ   S s Ś ś Ŝ ŝ Š š Ş ş Ș ș Ṣ ṣ ß   T t Ť ť Ţ ţ Ț ț Ṭ ṭ Þ þ   U u Ú ú Ù ù Û û Ü ü Ǔ ǔ Ŭ ŭ Ū ū Ũ ũ Ů ů Ų ų Ụ ụ Ű ű Ǘ ǘ Ǜ ǜ Ǚ ǚ Ǖ ǖ   V v   W w Ŵ ŵ   X x   Y y Ý ý Ŷ ŷ Ÿ ÿ Ỹ ỹ Ȳ ȳ   Z z Ź ź Ż ż Ž ž   ß Ð ð Þ þ Ŋ ŋ Ə ə
Greek: Ά ά Έ έ Ή ή Ί ί Ό ό Ύ ύ Ώ ώ   Α α Β β Γ γ Δ δ   Ε ε Ζ ζ Η η Θ θ   Ι ι Κ κ Λ λ Μ μ   Ν ν Ξ ξ Ο ο Π π   Ρ ρ Σ σ ς Τ τ Υ υ   Φ φ Χ χ Ψ ψ Ω ω   {{Polytonic|}}
Cyrillic: А а Б б В в Г г   Ґ ґ Ѓ ѓ Д д Ђ ђ   Е е Ё ё Є є Ж ж   З з Ѕ ѕ И и І і   Ї ї Й й Ј ј К к   Ќ ќ Л л Љ љ М м   Н н Њ њ О о П п   Р р С с Т т Ћ ћ   У у Ў ў Ф ф Х х   Ц ц Ч ч Џ џ Ш ш   Щ щ Ъ ъ Ы ы Ь ь   Э э Ю ю Я я   ́
IPA: t̪ d̪ ʈ ɖ ɟ ɡ ɢ ʡ ʔ   ɸ β θ ð ʃ ʒ ɕ ʑ ʂ ʐ ç ʝ ɣ χ ʁ ħ ʕ ʜ ʢ ɦ   ɱ ɳ ɲ ŋ ɴ   ʋ ɹ ɻ ɰ   ʙ ⱱ ʀ ɾ ɽ   ɫ ɬ ɮ ɺ ɭ ʎ ʟ   ɥ ʍ ɧ   ʼ   ɓ ɗ ʄ ɠ ʛ   ʘ ǀ ǃ ǂ ǁ   ɨ ʉ ɯ   ɪ ʏ ʊ   ø ɘ ɵ ɤ   ə ɚ   ɛ œ ɜ ɝ ɞ ʌ ɔ   æ   ɐ ɶ ɑ ɒ   ʰ ʱ ʷ ʲ ˠ ˤ ⁿ ˡ   ˈ ˌ ː ˑ ̪   {{IPA|}}

Wikidata entities used in this page

Pages transcluded onto the current version of this page (help):